Raymond James & Associates Has $5.13 Million Stock Position in DaVita Inc. (NYSE:DVA)

Raymond James & Associates increased its position in DaVita Inc. (NYSE:DVA) by 93.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 31,316 shares of the company’s stock after purchasing an additional 15,138 shares during the quarter. Raymond James & Associates’ holdings in DaVita were worth $5,134,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in shares of DaVita by 196.9% during the first quarter. SG Americas Securities LLC now owns 29,733 shares of the company’s stock valued at $4,105,000 after acquiring an additional 19,719 shares during the period. Bessemer Group Inc. lifted its holdings in shares of DaVita by 2,335.6% during the first quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock valued at $1,483,000 after acquiring an additional 10,300 shares during the period. Forsta AP Fonden lifted its holdings in shares of DaVita by 50.3% during the first quarter. Forsta AP Fonden now owns 23,600 shares of the company’s stock valued at $3,258,000 after acquiring an additional 7,900 shares during the period. Sei Investments Co. lifted its holdings in shares of DaVita by 21.3% during the first quarter. Sei Investments Co. now owns 41,952 shares of the company’s stock valued at $5,790,000 after acquiring an additional 7,371 shares during the period. Finally, BOKF NA lifted its holdings in shares of DaVita by 286,550.0% during the first quarter. BOKF NA now owns 5,733 shares of the company’s stock valued at $790,000 after acquiring an additional 5,731 shares during the period. 90.12% of the stock is owned by institutional investors.

DaVita Trading Up 1.2 %

Shares of DaVita stock opened at $141.51 on Friday. DaVita Inc. has a 12-month low of $76.64 and a 12-month high of $168.50. The stock has a market cap of $11.60 billion, a P/E ratio of 15.27, a P/E/G ratio of 0.82 and a beta of 0.87. The company has a quick ratio of 1.12, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The business’s 50 day moving average is $157.71 and its 200-day moving average is $146.05.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.85 EPS. Equities research analysts predict that DaVita Inc. will post 9.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DVA shares. TD Cowen lifted their price objective on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Bank of America boosted their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Truist Financial lifted their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Barclays lifted their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, UBS Group boosted their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.